L3VLUP
ProSign in

CLDX · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

CLDXLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • CLDX
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterCLDXLLY
Q3 20201 holders, $2.5m33 holders, $14.1bn
Q4 20203 holders, $7.7m29 holders, $17.3bn
Q1 20212 holders, $5.5m24 holders, $23.0bn
Q2 2021none listed holders, n.a.24 holders, $27.8bn
Q3 20211 holders, $41m31 holders, $29.9bn
Q4 20213 holders, $40m31 holders, $34.7bn
Q1 20223 holders, $83m24 holders, $35.3bn
Q2 20223 holders, $65m33 holders, $42.7bn
Q3 20222 holders, $5.7m31 holders, $43.4bn
Q4 20225 holders, $265m31 holders, $46.6bn
Q1 20232 holders, $152m33 holders, $44.3bn
Q2 20233 holders, $216m37 holders, $59.6bn
Q3 20233 holders, $189m44 holders, $67.6bn
Q4 20234 holders, $432m45 holders, $73.6bn
Q1 20244 holders, $444m41 holders, $95.3bn
Q2 20244 holders, $450m43 holders, $110bn
Q3 20243 holders, $447m45 holders, $107bn
Q4 20243 holders, $341m46 holders, $93.9bn
Q1 20253 holders, $221m42 holders, $98.4bn
Q2 20253 holders, $90m43 holders, $93.2bn
Q3 20253 holders, $253m39 holders, $86.7bn
Q4 20254 holders, $283m41 holders, $123bn
Q1 20264 holders, $393m39 holders, $106bn
Q2 20263 holders, $384m44 holders, $132bn
CLDX

Celldex Therapeutics Inc New

Holders
4
Reported value
$450m
Buyers
4
Sellers
0

Breadth +4 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUP
LLY

Eli Lilly & Co

Holders
43
Reported value
$110bn
Buyers
29
Sellers
17

Breadth +12 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 44 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only CLDX (1)

Point72 Asset Management LP

Only LLY (40)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, MFS Investment Management, Millennium Management LLC, and 15 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →